This clinical trial is focused on studying treatments for breast cancer, specifically in patients with a type of breast cancer that is estrogen receptor positive (ER+) and HER2 negative (HER2-). These patients have cancer that is either locally advanced or has spread to other parts of the body. The study involves several treatments: a new drug called imlunestrant, a combination of imlunestrant with another drug called abemaciclib, and standard treatments chosen by the study doctor, which may include either fulvestrant or exemestane.
The purpose of the study is to compare how well these treatments work in controlling the cancer. Participants will be randomly assigned to one of the treatment groups. Some will receive imlunestrant alone, some will receive the standard treatment chosen by the doctor, and others will receive a combination of imlunestrant and abemaciclib. The study will monitor the progress of the cancer and how it responds to the treatment over time.
Throughout the study, participants will take the medications either as tablets or as injections, depending on the treatment group they are in. The study aims to provide valuable information on the effectiveness of these treatments in managing advanced breast cancer, particularly in patients who have already been treated with drugs that block estrogen production.
Austria 
Belgium 
France 
Germany 
Greece 
Italy 
Spain 
The Netherlands